Manufacturer
Novartis
Contents
Timolol maleate
Indication
Elevated IOP in patients w/ ocular HTN or open-angle glaucoma
Instruction
1 drop in affected eye (s) once daily. Evaluate IOP after approx 4 wk of treatment, if clinical response is not adequate, concomitant therapy may be considered. Transferred from another topical ophth β-adrenergic blocking agent Discontinue after proper dosing on 1 day & start w/ 1 drop of 0.5% Timolast on following day. Transferred from single anti-glaucoma agent other than topical ophth β-adrenergic blocking agent Continue agent & add 1 drop of 0.5% Timolast in affected eye once daily, then discontinue previously used agent & continue 0.5% Timolast
Drug interaction
Potentiated systemic β-blockade w/ CYP2D6 inhibitors. Potential additive effects resulting in hypotension &/or marked bradycardia w/ oral Ca-channel blockers, β-adrenergic blocking agents, antiarrhythmics, digitalis glycosides, parasympathomimetics. Mydriasis w/ epinephrine.
Malaysia
